NCT00068783: S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer |
|
|
| Completed | 2 | 40 | US | imatinib mesylate, CGP 57148, Gleevec, Glivec, laboratory biomarker analysis | National Cancer Institute (NCI) | Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin | 06/07 | | | |
NCT00090987: Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma |
|
|
| Completed | 2 | 30 | US | imatinib mesylate, Gleevec | AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC | Sarcoma | 12/09 | 12/09 | | |
